Related Experiment Video

Updated: May 7, 2026

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Everolimus: a new hope for patients with breast cancer

Mehmet A N Sendur1, Nurullah Zengin, Sercan Aksoy

  • 1Ankara Numune Education and Research Hospital, Department of Medical Oncology , Ankara , Turkey.

Current Medical Research and Opinion
|September 21, 2013
PubMed
Abstract

Insights

Everolimus shows promise in treating breast cancer by inhibiting the mTOR pathway, improving outcomes for patients resistant to standard therapies. Further research is exploring its use in earlier disease stages.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Breast cancer can develop resistance to hormonal therapy and chemotherapy through mTOR pathway activation.
  • Everolimus, an mTOR inhibitor, has demonstrated improved outcomes when added to standard treatments in clinical trials.

Purpose of the Study:

  • To review the efficacy and safety data of everolimus in various breast cancer categories based on recent studies.
  • To discuss everolimus as a treatment strategy for endocrine therapy-resistant and HER2-targeted therapy-resistant breast cancer.

Main Methods:

  • Literature search of PubMed, ASCO, and San Antonio Breast Cancer Symposium abstracts.
  • Keywords used: 'everolimus', 'RAD001', 'mTOR inhibitor', 'breast cancer', 'endocrine therapy resistance', 'HER-2 targeted therapies'.
  • Data primarily from Phase I and II trials.

Main Results:

  • mTOR activation is implicated in breast cancer resistance across subgroups.
  • Everolimus combined with endocrine therapy (exemestane) showed efficacy in aromatase inhibitor-resistant metastatic breast cancer (MBC).
  • Everolimus plus trastuzumab and vinorelbine improved progression-free survival (PFS) in trastuzumab-resistant MBC.

Conclusions:

  • Everolimus demonstrates anti-tumor activity in combination therapies for HER2-positive and hormone-receptor-positive metastatic breast cancer.
  • Everolimus shows potential benefit in earlier disease stages, including adjuvant and neoadjuvant settings.

More Related Videos

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...